"Diphtheria Toxin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An ADP-ribosylating polypeptide produced by CORYNEBACTERIUM DIPHTHERIAE that causes the signs and symptoms of DIPHTHERIA. It can be broken into two unequal domains: the smaller, catalytic A domain is the lethal moiety and contains MONO(ADP-RIBOSE) TRANSFERASES which transfers ADP RIBOSE to PEPTIDE ELONGATION FACTOR 2 thereby inhibiting protein synthesis; and the larger B domain that is needed for entry into cells.
| Descriptor ID |
D004167
|
| MeSH Number(s) |
D08.811.913.400.725.115.220 D23.946.123.305
|
| Concept/Terms |
Diphtheria Toxin- Diphtheria Toxin
- Toxin, Corynebacterium Diphtheriae
- Corynebacterium Diphtheriae Toxin
|
Below are MeSH descriptors whose meaning is more general than "Diphtheria Toxin".
Below are MeSH descriptors whose meaning is more specific than "Diphtheria Toxin".
This graph shows the total number of publications written about "Diphtheria Toxin" by people in this website by year, and whether "Diphtheria Toxin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2019 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Diphtheria Toxin" by people in Profiles.
-
Targeted Apoptosis of Parietal Cells Is Insufficient to Induce Metaplasia in Stomach. Gastroenterology. 2017 03; 152(4):762-766.e7.
-
Retinal ganglion cell death and optic nerve degeneration by genetic ablation in adult mice. Exp Eye Res. 2009 Mar; 88(3):542-52.
-
Ablation of neurons expressing agouti-related protein activates fos and gliosis in postsynaptic target regions. J Neurosci. 2008 09 10; 28(37):9218-26.
-
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Haematol. 2007 Aug; 138(4):502-5.
-
Genetic ablation of cone photoreceptors eliminates retinal folds in the retinal degeneration 7 (rd7) mouse. Invest Ophthalmol Vis Sci. 2007 Jun; 48(6):2799-805.
-
Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol. 2007 Feb; 136(3):439-47.
-
Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides. J Clin Endocrinol Metab. 2006 Jun; 91(6):2205-8.
-
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol. 2004 Oct 15; 22(20):4095-102.
-
Cutaneous T-cell lymphoma. New immunomodulators. Dermatol Clin. 2001 Oct; 19(4):737-48.
-
Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001 Jan 15; 19(2):376-88.